We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+10.4%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$20.1B
AUM Growth
+$951M
Cap. Flow
-$224M
Cap. Flow %
-1.12%
Top 10 Hldgs %
32.44%
Holding
721
New
63
Increased
299
Reduced
261
Closed
36

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$55.1M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$46.1M
3
BABA icon
Alibaba
BABA
+$45M
4
NEE icon
NextEra Energy
NEE
+$40.9M
5
AMZN icon
Amazon
AMZN
+$38.3M

Top Sells

Rank Stock Value
1
EQIX icon
Equinix
EQIX
+$50.3M
2
META icon
Meta Platforms (Facebook)
META
+$44.2M
3
PG icon
Procter & Gamble
PG
+$34.1M
4
ZTS icon
Zoetis
ZTS
+$33.6M
5
CAH icon
Cardinal Health
CAH
+$32.2M

Sector Composition

Rank Sector Weight
1 Technology 34.01%
2 Healthcare 26.73%
3 Financials 11.13%
4 Consumer Discretionary 7.93%
5 Communication Services 7.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WRB icon
501
W.R. Berkley
WRB
$28.1B
$1.85M 0.01%
26,335
+7,210
+38% +$531K
EFX icon
502
Equifax
EFX
$22B
$1.84M 0.01%
8,501
-488
-5% -$107K
NTAP icon
503
NetApp
NTAP
$33.9B
$1.83M 0.01%
17,073
+3,047
+22% +$348K
LW icon
504
Lamb Weston
LW
$7.42B
$1.81M 0.01%
+43,274
New +$2.55M
DG icon
505
Dollar General
DG
$28.4B
$1.78M 0.01%
13,394
-1,683
-11% -$188K
MLTX icon
506
MoonLake Immunotherapeutics
MLTX
$1.56B
$1.77M 0.01%
134,329
+687
+0.5% +$8.11K
TER icon
507
Teradyne
TER
$50B
$1.76M 0.01%
9,095
+1,955
+27% +$335K
HOLX
508
DELISTED
Hologic
HOLX
$1.74M 0.01%
23,399
-375,878
-94% -$27.5M
LYV icon
509
Live Nation Entertainment
LYV
$42.9B
$1.7M 0.01%
11,953
-406
-3% -$58.4K
WFG icon
510
West Fraser Timber
WFG
$5.21B
$1.7M 0.01%
27,688
SO icon
511
Southern Company
SO
$108B
$1.67M 0.01%
+19,157
New +$1.75M
HHH icon
512
Howard Hughes
HHH
$3.94B
$1.67M 0.01%
20,908
+6,151
+42% +$510K
FWONK icon
513
Liberty Media Series C
FWONK
$25.5B
$1.62M 0.01%
16,475
+1,526
+10% +$150K
ERII icon
514
Energy Recovery
ERII
$420M
$1.62M 0.01%
119,714
-43,443
-27% -$659K
MAS icon
515
Masco
MAS
$14.6B
$1.6M 0.01%
25,263
-7,927
-24% -$514K
BNS icon
516
Scotiabank
BNS
$105B
$1.6M 0.01%
21,687
+3,666
+20% +$249K
OKTA icon
517
Okta
OKTA
$23.8B
$1.59M 0.01%
18,355
-96
-0.5% -$8.38K
BN icon
518
Brookfield
BN
$102B
$1.58M 0.01%
34,427
+14,448
+72% +$659K
BXP icon
519
Boston Properties
BXP
$11.6B
$1.58M 0.01%
23,420
-2,964
-11% -$211K
CPRT icon
520
Copart
CPRT
$28.5B
$1.58M 0.01%
40,231
-4,782
-11% -$198K
RSG icon
521
Republic Services
RSG
$67.4B
$1.57M 0.01%
7,399
-7,523
-50% -$1.62M
IFF icon
522
International Flavors & Fragrances
IFF
$20.3B
$1.54M 0.01%
22,919
+15,239
+198% +$987K
RDDT icon
523
Reddit
RDDT
$34.3B
$1.54M 0.01%
6,686
-2,791
-29% -$587K
SJM icon
524
J.M. Smucker
SJM
$13.5B
$1.54M 0.01%
15,700
SUI icon
525
Sun Communities
SUI
$15.8B
$1.52M 0.01%
12,279
+3,568
+41% +$447K

Similar funds

Candriam SCA's Q4 2025 Portfolio in Review

As of Q4 2025, Candriam SCA held 721 positions worth $20.1B, up 5% from $19.1B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Candriam SCA's Q4 2025 filing shows 63 new, 299 increased, 261 reduced and 36 closed positions. Its largest new stake was Alibaba: 276,080 shares worth $40.5M. The largest sale was Equinix, an estimated $50.3M.

By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 37% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q4 2025 buy was Alibaba: 276,080 shares worth $40.5M.
  • Candriam SCA added most to AbbVie in Q4 2025, an estimated $55.1M increase.
  • Candriam SCA's biggest Q4 2025 reduction was Equinix, cutting an estimated $50.3M.
  • Candriam SCA fully exited Universal Display in Q4 2025, selling an estimated $27.1M.
  • Candriam SCA's ten largest holdings make up 32% of its $20.1B portfolio in Q4 2025.
  • Candriam SCA opened 63 new positions and closed 36 in Q4 2025.
  • Candriam SCA's portfolio value rose 5% quarter-over-quarter to $20.1B.

Based on Candriam SCA's 13F filing for Q4 2025, filed 13 Feb 2026.